Global

Pharmaceutical Sciences Experts

Ms Joanna Horobin


Pharamaceutical Sciences
Nordic Nanovector
Norway

Biography

Ms Horobin has comprehensive experience within the biopharmaceutical industry. She is currently senior vice president, chief medical officer and a member of the leadership team at Idera Pharmaceuticals Inc. in Cambridge, MA, USA. Ms Horobin's current role includes the development and regulatory strategy as well as the execution of the clinical trial programme for the company's pipeline of novel oligonucleotides for the treatment of rare oncology and other indications. Prior to this position, she was chief medical officer of Verastem Inc., and chief executive officer of Syndax Pharmaceuticals. Additionally, Ms Horobin has held several roles of increasing responsibility at global pharmaceutical companies such as Rhône-Poulenc Rorer (now Sanofi) where she led the global launch of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (lenogratism) for colorectal cancer, and played significant leadership roles in the approvals of several successful products. Ms Horobin has served as a director in the company since October 2016. She is an independent director of the board. Ms Horobin has comprehensive experience within the biopharmaceutical industry. She is currently senior vice president, chief medical officer and a member of the leadership team at Idera Pharmaceuticals Inc. in Cambridge, MA, USA. Ms Horobin's current role includes the development and regulatory strategy as well as the execution of the clinical trial programme for the company's pipeline of novel oligonucleotides for the treatment of rare oncology and other indications. Prior to this position, she was chief medical officer of Verastem Inc., and chief executive officer of Syndax Pharmaceuticals. Additionally, Ms Horobin has held several roles of increasing responsibility at global pharmaceutical companies such as Rhône-Poulenc Rorer (now Sanofi) where she led the global launch of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (lenogratism) for colorectal cancer, and played significant leadership roles in the approvals of several successful products. Ms Horobin has served as a director in the company since October 2016. She is an independent director of the board.

Research Interest

Business Management

Global Experts from Norway

Global Experts in Subject

Share This Profile
Recent Expert Updates
  • Matthew L Stone
    Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.   Matthew
    Dr. Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone Matthew
    Dr. L Stone Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone
    Dr. L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr. Matthew L Stone
    Dr. Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  R Sameh
    Dr. R Sameh
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   R Ismail,
    Dr. R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Sameh R Ismail,
    Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   Sameh R Ismail,
    Dr. Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   William
    Dr. William
    pediatrics
    Maimonides Medical Center
    United States of America